美国预防服务工作组阿司匹林预防复发性子痫前期推荐的影响
本研究为回顾性队列研究,利用2家医院单一学术机构2011年8月至2016年6月数据库,比较美国预防服务工作组2014年发布阿司匹林预防子痫前期推荐前后有子痫前期病史女性的复发性子痫前期发生率。结果显示推荐发布后复发性子痫前期风险降低30%(校正相对风险0.70,95%CI 0.52-0.95)。
要点
- 美国预防服务工作组2014年推荐发布后,有子痫前期病史女性复发性子痫前期风险降低30%(校正RR 0.70,95%CI 0.52-0.95)。
- 复发性子痫前期危险因素包括年龄>35岁(RR 1.83)、医疗补助保险(RR 2.08)、2型糖尿病(RR 2.13)和慢性高血压(RR 1.96)。
- 作者建议未来前瞻性研究应直接评估阿司匹林依从性、开始孕周,并探索种族和民族对疗效的影响。
核心结论
- 美国预防服务工作组发布阿司匹林预防子痫前期推荐后,有子痫前期病史女性复发性子痫前期发生率降低30%(校正相对风险0.70,95%CI 0.52-0.95)。
研究设计与样本
- 回顾性队列研究,利用2家医院单一学术机构2011年8月至2016年6月数据库,共17,256次分娩,其中417名有子痫前期病史女性(推荐前284名,推荐后133名),排除多胎妊娠,多次分娩者仅纳入首次分娩。
主要发现
- 推荐后组西班牙裔女性比例较低,支付方式两组间存在差异(P<.0001)。
- 推荐后组1型糖尿病患病率增加,但孕前糖尿病总体率相似(推荐前6.3% vs 推荐后5.3%,P>.05)。
- 复发性子痫前期危险因素包括年龄>35岁(相对风险1.83,95%CI 1.34-2.48)、医疗补助保险(相对风险2.08,95%CI 1.15-3.78)、2型糖尿病(相对风险2.13,95%CI 1.37-3.33)和慢性高血压(相对风险1.96,95%CI 1.44-2.66)。
- 推荐后组复发性子痫前期风险降低30%(校正相对风险0.70,95%CI 0.52-0.95)。
关键数值与推荐
- 美国预防服务工作组推荐低剂量阿司匹林用于预防高风险的初发或复发子痫前期女性,该推荐于2014年9月发布。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性;作者在结论中建议未来前瞻性研究应直接评估阿司匹林依从性、开始孕周,并探索种族和民族对疗效的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The US Preventive Services Task Force recommends low-dose aspirin for the prevention of preeclampsia among women at high risk for primary occurrence or recurrence of disease. Recommendations for the use of aspirin for preeclampsia prevention were issued by the US Preventive Services Task Force in September 2014. OBJECTIVES: The objective of the study was to evaluate the incidence of recurrent preeclampsia in our cohort before and after the US Preventive Services Task Force recommendation for aspirin for preeclampsia prevention. STUDY DESIGN: This was a retrospective cohort study designed to evaluate the rates of recurrent preeclampsia among women with a history of preeclampsia. We utilized a 2-hospital, single academic institution database from August 2011 through June 2016. We excluded multiple gestations and included only the first delivery for women with multiple deliveries during the study period. The cohort of women with a history of preeclampsia were divided into 2 groups, before and after the release of the US Preventive Services Task Force 2014 recommendations. Potential confounders were accounted for in multivariate analyses, and relative risk and adjusted relative risk were calculated. RESULTS: A total of 17,256 deliveries occurred during the study period. A total of 417 women had a documented history of prior preeclampsia: 284 women before and 133 women after the US Preventive Services Task Force recommendation. Comparing the before and after groups, the proportion of Hispanic women in the after group was lower and the method of payment differed between the groups (P <.0001). The prevalence of type 1 diabetes was increased in the after period, but overall rates of pregestational diabetes were similar (6.3% before vs 5.3% after [P > .05]). Risk factors for recurrent preeclampsia included maternal age >35 years (relative risk, 1.83; 95% confidence interval, 1.34-2.48), Medicaid insurance (relative risk, 2.08; 95% confidence interval, 1.15-3.78), type 2 diabetes (relative risk, 2.13; 95% confidence interval, 1.37-3.33), and chronic hypertension (relative risk, 1.96; 95% confidence interval, 1.44-2.66). The risk of recurrent preeclampsia was decreased by 30% in the after group (adjusted relative risk, 0.70; 95% confidence interval, 0.52-0.95). CONCLUSION: Rates of recurrent preeclampsia among women with a history of preeclampsia decreased by 30% after release of the US Preventive Services Task Force recommendation for aspirin for preeclampsia prevention. Future prospective studies should include direct measures of aspirin compliance, gestational age at initiation, and explore the influence of race and ethnicity on the efficacy of this primary prevention.
引用
- Tolcher MC, Chu DM, Hollier LM, et al. Impact of USPSTF recommendations for aspirin for prevention of recurrent preeclampsia. Am J Obstet Gynecol. 2017. PMID: 28455079. doi:10.1016/j.ajog.2017.04.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。